(Q36161550)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

lung small cell carcinoma

25 March 2020

main subject

phase II clinical trial

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

9

Antonius A Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Timothy S Pardee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

William J Petty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Marcelo Bonomi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Angela Alistar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Zanetta S Lamar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Scott Isom

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Michael D Chan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Jimmy Ruiz

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

language of work or name

English

0 references

publication date

12 October 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

e0164244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons CC0 License

25 March 2020

copyright license

start time

12 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

cites work

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061374

10.1371/JOURNAL.PONE.0164244

2 July 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27732654%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference